NASDAQ:AMED Amedisys (AMED) Stock Price, News & Analysis $98.25 +0.50 (+0.51%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$97.63▼$98.9550-Day Range$91.15▼$98.3252-Week Range$89.55▼$98.95Volume1.40 million shsAverage Volume322,960 shsMarket Capitalization$3.21 billionP/E RatioN/ADividend YieldN/APrice Target$100.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Amedisys alerts: Email Address Amedisys MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside2.5% Upside$100.67 Price TargetShort InterestHealthy6.19% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment0.61Based on 13 Articles This WeekInsider TradingN/AProj. Earnings Growth8.75%From $4.57 to $4.97 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.10 out of 5 starsMedical Sector390th out of 936 stocksHome Health Care Services Industry4th out of 8 stocks 1.1 Analyst's Opinion Consensus RatingAmedisys has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAmedisys has only been the subject of 2 research reports in the past 90 days.Read more about Amedisys' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.19% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Amedisys has recently decreased by 14.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Previous Next 5.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmedisys has received a 82.47% net impact score from Upright. Amedisys seems to create the most significant positive value in categories "Jobs", "Meaning & joy", and "Taxes". The positive contribution in the "Meaning & joy" impact category is mostly driven by its "Private hospice care", "Private speech therapy services", and "Private occupational physiotherapy services" products. See details.Environmental SustainabilityThe Environmental Impact score for Amedisys is -0.61. Previous Next 2.6 News and Social Media Coverage News SentimentAmedisys has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Amedisys this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for AMED on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Amedisys to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Amedisys is held by insiders.Percentage Held by Institutions94.36% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amedisys' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Amedisys are expected to grow by 8.75% in the coming year, from $4.57 to $4.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is -153.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is -153.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 2.39. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Amedisys' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Amedisys Stock (NASDAQ:AMED)Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.Read More AMED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMED Stock News HeadlinesJuly 24 at 5:14 PM | gurufocus.comAmedisys Inc (AMED) Q2 2024 Earnings: EPS of $0.98 Misses Estimates, Revenue of $591. ...July 24 at 4:30 PM | globenewswire.comAmedisys Reports Second Quarter 2024 Financial ResultsJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 23 at 6:54 AM | lse.co.ukAmedisys Share Price (AMED.US)July 18, 2024 | americanbankingnews.comAmedisys, Inc. (NASDAQ:AMED) Receives Consensus Recommendation of "Hold" from AnalystsJune 9, 2024 | seekingalpha.comAmedisys shares could have downside to $74 a share in a no-deal scenario - analystMay 29, 2024 | finance.yahoo.comAREX Capital Management Issues Letter to Enhabit Stockholders Regarding the Need for Dramatic Changes to Board CompositionMay 22, 2024 | msn.comNurse charged with stealing pills while taking care of hospice patientJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 20, 2024 | msn.comAmedisys gains amid report about status of DOJ review of UnitedHealth dealMay 8, 2024 | msn.comAmedisys gains amid report of sweetened divestiture offer in UnitedHealth dealMay 7, 2024 | fool.comAmedisys (NASDAQ: AMED)May 1, 2024 | finance.yahoo.comAmedisys, Inc. (AMED)April 30, 2024 | msn.comUnitedHealth grew very big. Now, some lawmakers want to chop it down.April 25, 2024 | finanznachrichten.deAmedisys, Inc.: Amedisys Reports First Quarter 2024 Financial ResultsApril 25, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Hold Rating on Amedisys (AMED)April 25, 2024 | sfgate.comAmedisys: Q1 Earnings SnapshotApril 25, 2024 | investorplace.comAMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q1 2024See More Headlines Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/24/2024Today7/26/2024Next Earnings (Estimated)10/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Home health care services Sub-IndustryHealth Care Services Current SymbolNASDAQ:AMED CUSIP02343610 CIK896262 Webwww.amedisys.com Phone(225) 292-2031Fax225-292-8163Employees19,000Year Founded1982Price Target and Rating Average Stock Price Target$100.67 High Stock Price Target$101.00 Low Stock Price Target$100.00 Potential Upside/Downside+2.5%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E Ratio21.50 P/E Growth2.39Net Income$-9,750,000.00 Net Margins4.02% Pretax Margin1.43% Return on Equity12.56% Return on Assets6.82% Debt Debt-to-Equity Ratio0.31 Current Ratio1.09 Quick Ratio1.09 Sales & Book Value Annual Sales$2.24 billion Price / Sales1.44 Cash Flow$6.16 per share Price / Cash Flow15.96 Book Value$34.31 per share Price / Book2.86Miscellaneous Outstanding Shares32,680,000Free Float32,089,000Market Cap$3.21 billion OptionableOptionable Beta0.79 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMs. Allyson GuidrozChief Accounting Officer & Principal Accounting OfficerMs. Jennifer Guckert GriffinSenior VP, Deputy General Counsel, Corporate Secretary & Interim Chief Legal OfficerKendra KimmonsVP of Marketing & Communications & Media RelationsMr. Adam Holton (Age 53)Chief People Officer Mr. Francis MayerSenior Vice President of DevelopmentKey CompetitorsLHC GroupNASDAQ:LHCGDaVitaNYSE:DVAChemedNYSE:CHER1 RCMNASDAQ:RCMCorVelNASDAQ:CRVLView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 467 shares on 7/26/2024Ownership: 0.827%GAM Holding AGBought 3,000 shares on 7/26/2024Ownership: 0.009%Calamos Advisors LLCBought 41,220 shares on 7/25/2024Ownership: 1.216%Retirement Systems of AlabamaSold 702 shares on 7/24/2024Ownership: 0.123%Louisiana State Employees Retirement SystemSold 200 shares on 7/24/2024Ownership: 0.028%View All Institutional Transactions AMED Stock Analysis - Frequently Asked Questions How have AMED shares performed this year? Amedisys' stock was trading at $95.06 at the start of the year. Since then, AMED shares have increased by 3.4% and is now trading at $98.25. View the best growth stocks for 2024 here. How were Amedisys' earnings last quarter? Amedisys, Inc. (NASDAQ:AMED) announced its earnings results on Wednesday, April, 24th. The health services provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. The firm's revenue for the quarter was up 2.7% compared to the same quarter last year. What is Paul B. Kusserow's approval rating as Amedisys' CEO? 478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend. Who are Amedisys' major shareholders? Top institutional investors of Amedisys include Calamos Advisors LLC (1.22%), Bank of New York Mellon Corp (0.83%), Van Lanschot Kempen Investment Management N.V. (0.80%) and Retirement Systems of Alabama (0.12%). Insiders that own company stock include Christopher Gerard, Bruce D Perkins, David L Kemmerly, Denise M Bohnert, Michael Paul North and Richard A Lechleiter. View institutional ownership trends. How do I buy shares of Amedisys? Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC) and QUALCOMM (QCOM). This page (NASDAQ:AMED) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amedisys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
